TEST:

Thyroid GuidePx®

P=N/A; N=130; Not yet recruiting; Sponsor:University of Calgary

P=N/A; N=130; Not yet recruiting; Sponsor:University of Calgary

"Dr. Oliver Bathe presented results from a study of 742 patients at the 2022 Annual Meeting of the American Thyroid Association. The study demonstrated that Thyroid GuidePx® has a 97% specificity in identifying patients with low-risk papillary thyroid cancer. This is much more accurate than the 80% specificity the conventional ATA risk stratification system identifies."

The 5‐year recurrence rate for early Type 1 PTC (enriched with Ras‐like follicular variants) was significantly lower in early PTC in comparison to advanced PTC (3.7% vs. 12%). Similarly, early Type 2 PTC had a much lower recurrence rate in comparison to advanced cancers (1.2% vs.

Thyroid GuidePx was capable of yielding repeatable gene expression measures. A classification algorithm customized for FFPE enabled reliable and repeatable classification of molecular subtypes.

"Protean BioDiagnostics and Qualisure Diagnostics Inc. announced...that both companies have entered into a strategic partnership to launch a novel diagnostic test for thyroid cancer. Thyroid GuidePx® is the first genomic classifier for papillary thyroid cancer, designed to assist clinicians treating thyroid cancer in making treatment decisions."